Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of PBI-4050 in Alström syndrome
2015-001625-16Phase 2Completed
- Sponsor
- Liminal BioSciences Inc.
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fezagepras in Alström syndrome (ALMS), sponsored by Liminal BioSciences Inc. Primary endpoint: Safety and tolerability of PBI-4050 over 24 weeks. Started Sep 2015; status: completed.
02
Drugs
fezagepras
03
Conditions
Alström syndrome (ALMS)
Beyond the preview
Go deeper on 2015-001625-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001625-16.